Carcinosarcomas of the Uterus: Prognostic Factors and Impact of Adjuvant Treatment

References

• Matsuo K , Ross MS , Machida H , Blake EA , Roman LD . Trends of uterine carcinosarcoma in the United States. J Gynecol Oncol . 2018;29(2):e22. doi:10.3802/jgo.2018.29.e22 29400015
   PubMed Web of Science ®Google Scholar
• Denschlag D , Ulrich UA . Uterine Carcinosarcomas - Diagnosis and Management. Oncol Res Treat . 2018;41(11):675–679. doi:10.1159/000494335 30317231
   PubMed Web of Science ®Google Scholar
• Kernochan LE , Garcia RL . Carcinosarcomas (malignant mixed Mullerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw . 2009;7(5):550–556; quiz 557. doi:10.6004/jnccn.2009.0037
   PubMed Web of Science ®Google Scholar
• Zelmanowicz A , Hildesheim A , Sherman ME , et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol . 1998;69(3):253–257. doi:10.1006/gyno.1998.4941 9648597
   PubMed Web of Science ®Google Scholar
• Cantrell LA , Blank SV , Duska LR . Uterine carcinosarcoma: a review of the literature. Gynecol Oncol . 2015;137(3):581–588. doi:10.1016/j.ygyno.2015.03.041 25805398
   PubMed Web of Science ®Google Scholar
• Vorgias G , Fotiou S . The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet . 2010;282(6):659–664. doi:10.1007/s00404-010-1649-0 20721670
   PubMed Web of Science ®Google Scholar
• Versluis MAC , Pielsticker C , van der Aa MA , de Bruyn M , Hollema H , Nijman HW . Lymphadenectomy and adjuvant therapy improve survival with uterine carcinosarcoma: a large retrospective cohort Study. Oncology . 2018;95(2):100–108. doi:10.1159/000488531 29791913
   PubMed Web of Science ®Google Scholar
• Temkin SM , Hellmann M , Lee YC , Abulafia O . Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer . 2007;17(1):215–219. doi:10.1111/j.1525-1438.2006.00762.x 17291256
   PubMed Web of Science ®Google Scholar
• Menczer J . Review of recommended treatment of uterine carcinosarcoma. Curr Treat Options Oncol . 2015;16(11):53. doi:10.1007/s11864-015-0370-4 26374341
   PubMed Web of Science ®Google Scholar
• Homesley HD , Filiaci V , Markman M , et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol . 2007;25(5):526–531. doi:10.1200/JCO.2006.06.4907 17290061
   PubMed Web of Science ®Google Scholar
• Sutton G , Kauderer J , Carson LF , et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol . 2005;96(3):630–634. doi:10.1016/j.ygyno.2004.11.022 15721404
   PubMed Web of Science ®Google Scholar
• Heinzelmann-Schwarz V , Kind AB , Vetter M , et al. Should MMMT still be treated with adjuvant taxane-based combination chemotherapy? J Cancer Res Clin Oncol . 2020;146(3):695–704. doi:10.1007/s00432-019-03091-y 31993743
   PubMed Web of Science ®Google Scholar
• Powell MA , Filiaci VL , Rose PG , et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol . 2010;28(16):2727–2731. doi:10.1200/JCO.2009.26.8326 20421537
   PubMed Web of Science ®Google Scholar
• Berton-Rigaud D , Devouassoux-Shisheboran M , Ledermann JA , et al. Gynecologic cancer interGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer . 2014;24(9 Suppl 3):S55–60. doi:10.1097/IGC.0000000000000228 25341582
   PubMed Web of Science ®Google Scholar
• Kanthan R , Senger JL . Uterine carcinosarcomas (malignant mixed mullerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int . 2011;2011:470795. doi:10.1155/2011/470795 22007228
   PubMedGoogle Scholar
• Gonzalez Bosquet J , Terstriep SA , Cliby WA , et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol . 2010;116(3):419–423. doi:10.1016/j.ygyno.2009.10.053 19896181
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statisitics . SEIFA 2011 socio-economic indexes for areas; 2011.
   Google Scholar
• Department of Health and Aged Care. Measuring remoteness: Accessibility/Remoteness Index of Australia (ARIA), Revised Edition. Occasional Paper. Canberra: Department of Health and Aged Care 2011.
   Google Scholar
• National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology: uterine neoplasms v1.2021. NCCN.org; 2020. Accessed 2 16, 2021.
   Google Scholar
• Abdulfatah E , Lordello L , Khurram M , et al. Predictive histologic factors in carcinosarcomas of the uterus: a multi-institutional Study. Int J Gynecol Pathol . 2019;38(3):205–215. doi:10.1097/PGP.0000000000000497 30958427
   PubMed Web of Science ®Google Scholar
• Dickson EL , Vogel RI , Gehrig PA , et al. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. Gynecol Oncol . 2015;139(2):275–282. doi:10.1016/j.ygyno.2015.09.002 26348313
   PubMed Web of Science ®Google Scholar
• Makker V , Abu-Rustum NR , Alektiar KM , et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol . 2008;111(2):249–254. doi:10.1016/j.ygyno.2008.06.035 18755503
   PubMed Web of Science ®Google Scholar
• Cha J , Kim YS , Park W , et al. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08). J Gynecol Oncol . 2016;27(6):e58. doi:10.3802/jgo.2016.27.e58 27550404
   PubMed Web of Science ®Google Scholar
• Li Y , Ren H , Wang J . Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study. BMC Cancer . 2019;19(1):697. doi:10.1186/s12885-019-5879-7 31307426
   PubMed Web of Science ®Google Scholar
• Gungorduk K , Ozdemir A , Ertas IE , et al. Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas. Cancer Res Treat . 2015;47(2):282–289. doi:10.4143/crt.2014.009 25358384
   PubMed Web of Science ®Google Scholar
• Vitale SG , Lagana AS , Capriglione S , et al. Target therapies for uterine carcinosarcomas: current evidence and future perspectives. Int J Mol Sci . 2017;18(5):1100. doi:10.3390/ijms18051100
   PubMed Web of Science ®Google Scholar
• Menczer J , Levy T , Piura B , et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol . 2005;97(1):166–170. doi:10.1016/j.ygyno.2004.12.006 15790453
   PubMed Web of Science ®Google Scholar
• Matsuzaki S , Klar M , Matsuzaki S , Roman LD , Sood AK , Matsuo K . Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol . 2020.
   Web of Science ®Google Scholar
• Garg G , Yee C , Schwartz K , Mutch DG , Morris RT , Powell MA . Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis. Gynecol Oncol . 2014;133(2):242–249. doi:10.1016/j.ygyno.2014.02.021 24561247
   PubMed Web of Science ®Google Scholar
• Kimyon Comert G , Turkmen O , Boyraz G , et al. Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study. Balkan Med J . 2019;36(4):229–234. doi:10.4274/balkanmedj.galenos.2019.2018.12.75 30873825
   PubMed Web of Science ®Google Scholar
• Kurnit KC , Previs RA , Soliman PT , et al. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol . 2019;152(1):31–37. doi:10.1016/j.ygyno.2018.10.034 30414738
   PubMed Web of Science ®Google Scholar
• Nemani D , Mitra N , Guo M , Lin L . Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol . 2008;111(1):82–88. doi:10.1016/j.ygyno.2008.05.016 18674808
   PubMed Web of Science ®Google Scholar
• Reed NS , Mangioni C , Malmstrom H , et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer . 2008;44(6):808–818. doi:10.1016/j.ejca.2008.01.019 18378136
   PubMed Web of Science ®Google Scholar
• Wolfson AH , Brady MF , Rocereto T , et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol . 2007;107(2):177–185. doi:10.1016/j.ygyno.2007.07.070 17822748
   PubMed Web of Science ®Google Scholar
• Manzerova J , Sison CP , Gupta D , et al. Adjuvant radiation therapy in uterine carcinosarcoma: a population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. Gynecol Oncol . 2016;141(2):225–230. doi:10.1016/j.ygyno.2016.02.013 26896827
   PubMed Web of Science ®Google Scholar
• Zhu J , Wen H , Bi R , Wu X . Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. J Gynecol Oncol . 2016;27(2):e18. doi:10.3802/jgo.2016.27.e18 26463439
   PubMed Web of Science ®Google Scholar
• Alagkiozidis I , Weedon J , Grossman A , et al. Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: a retrospective cohort study. Int J Surg . 2015;24(Pt A):9–13. doi:10.1016/j.ijsu.2015.10.006 26476418
   PubMed Web of Science ®Google Scholar
• Otsuki A , Otsuki T , Tokunaga H , et al. Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit. Int J Clin Oncol . 2015;20(3):574–578. doi:10.1007/s10147-014-0732-0 25030547
   PubMed Web of Science ®Google Scholar
• Sagae S , Yamashita K , Ishioka S , et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology . 2004;67(1):33–39. doi:10.1159/000080283 15459493
   PubMed Web of Science ®Google Scholar